Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Más filtros

Bases de datos
Tipo del documento
Intervalo de año de publicación
1.
Biosens Bioelectron ; 179: 113042, 2021 May 01.
Artículo en Inglés | MEDLINE | ID: mdl-33662816

RESUMEN

Fast detection of pathogens is important for protecting our health and society. Herein, we present a high-performance nanogap impedimetric sensor for monitoring nucleic acid amplification in real time using isothermal recombinase polymerase amplification (RPA) for rapid pathogen detection. The nanogap electrode chip has two pairs of opposing gold electrodes with a 100 nm gap and was fixed to a PCB. Then, the nanogap impedimetric sensor was immersed in RPA reaction solution for the detection of E. coli O157:H7, and target DNA amplification was evaluated through bulk solution impedance changes using impedance spectroscopy every minute during RPA. In addition, target gene amplification in the sample solution during RPA was confirmed with a 2% DNA agarose gel. Our nanogap impedimetric sensor can detect down to a single copy of the eae A gene in gDNA extracted from E. coli O157:H7 as well as a single cell of pathogenic E. coli O157:H7 strain within 5 min during direct RPA, which was performed with the pathogen itself and without the extraction and purification of target gDNA. The miniaturized nanogap impedimetric sensor has potential as a cost-effective point-of-care device for fast and accurate portable pathogen detection via real-time nucleic acid analysis.


Asunto(s)
Técnicas Biosensibles , Escherichia coli O157 , ADN , Escherichia coli O157/genética , Técnicas de Amplificación de Ácido Nucleico , Recombinasas/genética , Sensibilidad y Especificidad
2.
Bioorg Med Chem Lett ; 18(20): 5372-6, 2008 Oct 15.
Artículo en Inglés | MEDLINE | ID: mdl-18835158

RESUMEN

Extracellular signal-regulated kinase 2 (ERK2) has become an attractive target for the development of therapeutics for the treatment of cancer. We have been able to identify eight new inhibitors of ERK2 by means of a drug design protocol involving the virtual screening with docking simulations and in vitro enzyme assay. The newly discovered inhibitors can be categorized into three structural classes and reveal a significant potency with IC(50) values ranging from 1 to 30 microM. Therefore, all of the three inhibitor scaffolds deserve further development by structure-activity relationship or de novo design methods. Structural features relevant to the stabilizations of the newly identified inhibitors in the ATP-binding site of ERK2 are discussed in detail.


Asunto(s)
Antineoplásicos/farmacología , Química Farmacéutica/métodos , Inhibidores Enzimáticos/farmacología , Proteína Quinasa 1 Activada por Mitógenos/antagonistas & inhibidores , Neoplasias/tratamiento farmacológico , Adenosina Trifosfato/química , Antineoplásicos/síntesis química , Sitios de Unión , Diseño de Fármacos , Inhibidores Enzimáticos/síntesis química , Humanos , Concentración 50 Inhibidora , Proteína Quinasa 1 Activada por Mitógenos/química , Modelos Químicos , Modelos Moleculares , Modelos Estadísticos , Conformación Molecular , Proteínas Quinasas p38 Activadas por Mitógenos/metabolismo
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA